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Background: The inappropriate secretion of adipocytokines plays a critical role in chronic inflammatory states
associated with obesity-linked type 2 diabetes and atherosclerosis. The pleiotropic actions of simvastatin and
pioglitazone on epicardial adipose tissue (EAT) are unknown. This study assessed the anti-inflammatory actions of
simvastatin and pioglitazone on EAT in patients with coronary artery disease (CAD) and metabolic syndrome (MS).
Methods: A total of 73 patients with multivessel CAD who underwent elective bypass grafting were non-randomly
allocated to one of four subgroups: Control (n = 17), simvastatin (20 mg/day, n = 20), pioglitazone (15 mg or 30 mg/day,
n = 18), or simvastatin + pioglitazone (20 mg/day + 30 mg/day, respectively, n = 18); 20 valvar patients were also
included. EAT samples were obtained during surgery. The infiltration of macrophages and lymphocytes and
cytokines secretion were investigated using immunohistochemical staining and compared to plasma
inflammatory biomarkers.
Results: Simvastatin significantly reduced plasma interleukin-6, leptin, resistin and monocyte chemoattractant
protein-1 (p < 0.001 for all); pioglitazone reduced interleukin-6, tumoral necrose factor-alpha, resistin and matrix
metalloproteinase-9 (p < 0.001 for all). Simvastatin + pioglitazone treatment further reduced plasmatic variables,
including interleukin-6, tumoral necrose factor-alpha, resistin, asymmetric dimethylarginine and metalloproteinase-9 vs.
the control group (p < 0.001). Higher plasma adiponectin and lower high sensitivity C-reactive protein concentrations
were found simultaneously in the combined treatment group. A positive correlation between the mean percentage
systemic and tissue cytokines was observed after treatments. T- and B-lymphocytes and macrophages clusters were
observed in the fat fragments of patients treated with simvastatin for the first time.
Conclusions: Pioglitazone, simvastatin or combination treatment substantially reduced EAT and plasma inflammatory
markers in CAD and MS patients. These tissue effects may contribute to the control of coronary atherosclerosis
progression.
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Adipose tissue stores and releases energy, and it also exerts
important autocrine/paracrine and endocrine functions,
especially through the secretion of bioactive cytokines
known as adipokines. Therefore, visceral fat accumulation
causes inflammatory cells infiltration and cytokine expression.
Adipose tissue macrophages play a critical role in chronic
inflammatory states [1] that are associated with obesity-
linked diseases, such as diabetes and atherosclerosis [2-4].
Epicardial adipose tissue (EAT) has received consider-
able attention. EAT is a recognized source of inflamma-
tory cytokines, which may contribute to the pathogenesis
of coronary atherosclerotic lesions [5]. Inflammatory me-
diators from extravascular adipocytes promote coronary
artery disease, which may explain the increased cardiovas-
cular risk in patients with insulin resistance [6], especially
in obese individuals [7]. Several human studies indicate
that pericardial fat deposits are more metabolically active
than subcutaneous adipose tissue [5,6]. For example, EAT
from patients undergoing coronary bypass grafting con-
tained significantly more interleukin-1β (IL-1β), interleukin-
6 (IL-6), monocyte chemoattractant protein-1 (MCP-1)
and tumoral necrose factor-α (TNF-α) mRNA and protein
than subcutaneous adipose tissue [5]. Cytokine concentra-
tions in epicardial fat correlated with an accumulation of
inflammatory cells, such as T-lymphocytes, macrophages
and mast cells, in the vicinity of EAT. Epicardial mRNA
levels for CD45, a marker of macrophage infiltration, were
significantly increased compared to abdominal fat from
patients subjected to bypass grafting [6]. The infiltration
of macrophages and CD-8-positive T cells in the EAT of
patients subjected to bypass was greater than patients who
underwent surgery for aortic or mitral valve replacement
[8]. Finally, patients with advanced CHD exhibited lower
epicardial adiponectin levels, which may contribute to the
increased cardiovascular risk [9-11].
Obesity predisposes humans and animals to an accumu-
lation of excess epicardial fat [6,12], and its mass, assessed
using transthoracic echocardiography and magnetic res-
onance in healthy subjects, may be a novel indicator of
cardiovascular risk [13,14]. These facts support the im-
portance of analyses of therapeutic interventions to inter-
fere with EAT [15]. Pioglitazone and simvastatin have
pleiotropic effects and reduce pro-inflammatory markers
and improve insulin sensitivity [16-18]. However, no docu-
mentation of change in EAT inflammatory cell expression
and adipokines after Simvastatin and/or Pioglitazone ther-
apies in CAD patients with MS. This study assessed the
anti-inflammatory effects of these compounds on EAT
and correlated them with plasma/tissue inflammatory
markers because tissue effect is an objective criteria for
drug evaluations. Our findings demonstrated strong anti-
inflammatory actions on EAT and excellent correlations
between plasma and tissue effects.Methods
Subjects
The Ethics Committee of the Heart Institute (InCor)
and Hospital das Clinicas of the University of São Paulo
Medical School approved the protocol. Seventy-three
consecutive patients with multivessel CAD and MS who
underwent bypass grafting and 20 valvar patients who
underwent surgery for mitral valve replacement were
enrolled. The attending heart team allocated the 73
CAD patients to one of four groups based on clinical
and angiographic evaluation: control (n = 17), simvastatin
alone (20 mg/day, n = 20), pioglitazone alone (30 mg/day,
n = 18), or simvastatin + pioglitazone (20 mg/day + 30 mg/day,
respectively, n = 18). Randomization was not necessary
because the primary objective of the study was to correlate
plasma and tissue effects rather than directly compare the
two drugs. Treatments were initiated three months before
surgery and maintained until the operation. All subjects
who received pioglitazone were type 2 diabetics. No lipid-
lowering drugs were administered in the control and pio-
glitazone groups, and statins were initiated during the in-
hospital postoperative period. MS was defined according
to NCEP-ATP III criteria [19,20]. Patients affected by liver
disease, renal failure, neoplastic diseases, HIV positive,
metabolic diseases, or those who smoked were excluded.
Written informed consent was obtained from each patient.
Blood collection
Peripheral venous blood was drawn into pyrogen-free tubes
with or without EDTA as an anticoagulant immediately
before surgery after 10–12 h overnight fast. Plasma glu-
cose was determined using spectrophotometric methods
(Glucose Flex Reagent Cartridge, Dade Behring). An
ELISA kit (R&D Systems) quantified adiponectin, leptin,
resistin, MCP-1, matrix metalloproteinase-9 (MMP-9)
and asymmetric dimethylarginine (ADMA) in human
serum. IL-6, TNF-α and insulin concentrations in hu-
man serum were quantified using the enzyme immuno-
metric assay, Immulite 2000. Quantification of serum
HbA1c level was accomplished using the Hemoglobin
A1c test Tinaquant II Roche/Hitachi system.
Immunohistochemical staining
Adipose tissue samples (average 0.5-1.0 g) were taken
near the proximal tract of the right coronary artery at
the beginning of surgery for cardiopulmonary bypass be-
fore heparin administration. Tissue was formalin-fixed,
and paraffin-embedded tissue sections were deparaffi-
nized in xylene and dehydrated in a graded series of
ethanol. Endogenous peroxidase activity was quenched
using 6% hydrogen peroxide, followed by incubation with
CAS-Block™ Invitrogen for 10 min. Antigen retrieval was
performed in Tris-ethylenediaminetetraacetic acid buf-
fer (pH 9.0) for 10 min. Immunohistochemical staining
Table 1 Demographic characteristics
Valvar
(n = 20)










Age (yrs) 52.3 ± 8.0 <0.001 64.3 ± 6.06 60.1 ± 6.38 57.6 ± 5.89 60.1 ± 7.08 0.024
Male (%) 6(30) 0.005 12(70.6) 16(80) 10 (55.6) 10 (55.6) 0.314
Waist circumference (cm) 78.4 ± 11.9 <0.001 103.6 ± 6.43 103.2 ± 8.62 103.7 ± 8.09 105.2 ± 9.06 0.883
Systolic BP (mmHg) 113 ± 10.3 <0.001 145 ± 17.1 134 ± 15.1 162 ± 20.3 145 ± 13.8 <0.001
Diastolic BP (mmHg) 72 ± 11.5 0.006 87 ± 11.8 78 ± 10.3 85 ± 12 73 ± 11.2 0.001
Baseline Weight (Kg) 58.9 ± 12.4 <0.001 85.8 ± 13.7 76.7 ± 10.8 80.6 ± 13.7 83.9 ± 10.2 0.122
Final Weight (Kg) 57.2 ± 11.9 <0.001 82.5 ± 12.9 74.6 ± 10.5 81.4 ± 14.6 83.3 ± 9.3 0.102
Values are means ± SD or n(%). CAD = coronary artery disease; BP = blood pressure. P* value = Comparison between non-CAD group and CAD/MS group. P** value =
Comparison between CAD/MS groups.
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antibodies against CD20/lymphocytes B (1:1000, clone
L26, Dako, Denmark), CD45/lymphocytes T (1:5, clone
UCHL, Dako, Denmark), CD68/macrophages (1:320, clone
KP-1, Dako, Denmark), alpha tumor necrosis factor (TNF-α)
(1:20, clone 28401, R&D System, UK), interleukin-6 (IL-6)
(1:10, clone 1936, R&D System, UK), adiponectin (1:2000,
clone 6D, US Biological), leptin (1:10, clone AF 398, R&D
System, UK) and resistin (1:50, clone LS-B2879, Lifespan,
USA) followed by incubation with the secondary antibody
Picture ™MAX Polymer Invitrogen. Localization of the pri-






TG (mg/dL) 103.1 ± 40.48 0.002 162.88 ± 55.89
LDL-c (mg/dL) 103.5 ± 29.68 0.381 123.76 ± 19.13
HDL-c (mg/dL) 44.1 ± 13.88 <0.001 34.35 ± 3.9
Glucose (mg/dL) 82.95 ± 11.77 <0.001 101.18 ± 12.34
HbA1c (%) 5.63 ± 0.41 0.003 5.78 ± 0.49
Urea (mg/dL) 17 ± 4.11 0.3 25 ± 7.5
Creatinine (mg/dL) 0.9 ± 0.2 0.42 1.1 ± 0.8
hsCRP (mg/L) 3.89 ± 1.49 0.466 7.42 ± 1.45
IL-6 (pg/mL) 3.51 ± 0.95 0.811 5.3 ± 1.06
TNF-α (pg/mL) 14.71 ± 4.06 0.317 16.58 ± 2.4
Leptin (pg/mL) 3519.75 ± 1997.54 <0.001 17043.69 ± 2065.78
Resistin (ng/mL) 4.34 ± 1.09 <0.001 12.1 ± 1.38
Adiponectin (mg/mL) 15280 ± 4389.45 <0.001 1480.59 ± 426.02
MCP-1 (pg/mL) 73 ± 6.23 <0.001 341.93 ± 66.16
ADMA (μmol/L) 0.47 ± 0.13 0.595 0,53 ± 0.14
MMP-9 (ng/mL) 553.35 ± 157.38 0.146 577.08 ± 147.01
Values are means ± SD. TG = triglyceride; LDL = low-density lipoprotein cholesterol;
Pioglitazone only and Simvastatin + pioglitazone groups, the baseline values of glucos
TNF-α = tumoral necrosis factor. P* value = Comparison between non-CAD group andand counter-stained with hematoxylin. The percentage of
positive area for cells and inflammatory markers was
counted in three fields (edges, center and adjacent to ves-
sels) using an image analyzer (Leica Cambridge Quanti-
met) with a 20X objective in a double-blind fashion.
Statistical analysis
The data are expressed as the means ± standard deviation
(SD). One-way ANOVA followed by Bonferroni test com-
pared the mean values of continuous variables between
treatment groups followed by post hoc analysis. The sam-









152 ± 68.64 167.89 ± 61.29 110.39 ± 22.1 0.011
92.45 ± 33.57 142 ± 31.15 89.06 ± 25.62 <0.001
40.25 ± 7.5 41.39 ± 8.36 41.89 ± 6.33 0.006
93.2 ± 17.11 120.44 ± 23.99* 144.44 ± 31.89* <0.001
5.59 ± 0.57 6.72 ± 1.55 6.41 ± 1.16 0.004
21 ± 3.3 31 ± 2.22 30 ± 2.24 0.011
1.0 ± 0.42 1.2 ± 0.9 1,25 ± 0.7 0.01
1.93 ± 1.59 2.97 ± 1.21 1.88 ± 0.65 <0.001
3.29 ± 1.15 3.15 ± 1.15 2.68 ± 0.69 <0.001
18.28 ± 10.91 7.92 ± 1.03 8.65 ± 2.1 <0.001
4836.25 ± 1310.68 42899.54 ± 9011.58 13979.94 ± 1622.5 <0.001
6.41 ± 0.97 5.41 ± 1.32 7.41 ± 0.99 <0.001
4601.85 ± 1044.07 6099.38 ± 1227.84 7427.43 ± 1229.81 <0.001
66.48 ± 11.2 381.55 ± 69.28 325.98 ± 62.07 <0.001
0.47 ± 0.12 0.44 ± 0.33 0.34 ± 0.11 0.05
672.65 ± 340.37 216.54 ± 32.6 362.76 ± 103.57 <0.001
HDL = high-density lipoprotein cholesterol; HbA1c = hemoglobin A1c. In the
e were higher than final values. hsCRP = C-reactive protein IL-6 = interleukin-6;
CAD/MS group. P** value = Comparison between CAD/MS groups.
Figure 1 Immunohistochemical staining in the EAT: quantify
area. (A) Average percentage area for pro- and anti-inflammatory
cytokines in the EAT (P < 0.005). TNF-α: tumoral necrosis factor alpha;
IL-6: interleukin 6. Analysis of variance one-way ANOVA; Bonferroni
post-hoc test. (B) Average percentage area for CD68+ macrophages,
CD45 T- and CD20 B-lymphocytes in EAT according to treatment
group. (p < 0.05) for comparisons between CAD/MS groups, except
for the comparison between the percentage of T-lymphocytes of
pioglitazone and control groups (p = 0.236), and the percentage of
macrophages using monotherapy with pioglitazone and simvastatin
treatments (p = 0.349). CD45 T and CD20 B cells formed inflammatory
clusters close to the edge of and around vessels of the EAT sections
in the simvastatin group, but the center of the fat fragment was free
of inflammatory cells. CD68+: macrophages; CD45T: T lymphocytes;
CD20B: B lymphocytes. Analysis of variance: one-way ANOVA;
Bonferroni post-hoc test. See text for details.
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adiponectin/actin ratio) in adiponectin protein expression
between the CAD and valvar groups. Two-tailed p < 0.05
indicated statistical significance. Analyses were performed
using SPSS version 19.
Results
Demographic data
Patient demographic characteristics are summarized in
Table 1. CAD/MS patients were significantly older and
had larger waist circumferences and higher initial and
final weights than the valvar group. CAD/MS groups
were homogeneous for males sex (65.7%) and waist cir-
cumference. All CAD/MS subjects were hypertensive,
10% suffered a myocardial infarction in the past, 2%
underwent a coronary angioplasty and 2% had previous
CABG. Left ventricular ejection fraction, as assessed
using LV angiogram, was above 45% in all patients.
Laboratory data
Table 2 summarizes final laboratory values. The majority
of CAD/MS groups had higher triglycerides, HDL-c, glu-
cose, HbA1c, leptin, resistin and MCP-1 plasma levels
than valvar patients. Valvar patients showed higher plasma
adiponectin than patients with CAD/MS (p < 0.001).
Treatment effects on blood parameters
Treatment with simvastatin alone, pioglitazone alone and
simvastatin + pioglitazone significantly reduced plasma
CRP in CAD/MS patients compared to the control group
(p < 0.001). Simvastatin monotherapy significantly reduced
plasma IL-6, leptin, resistin and MCP-1 (p < 0.001 for all),
but pioglitazone monotherapy reduced IL-6, TNF-α, resis-
tin and MMP-9 compared to the control group (p < 0.001
for all). Finally, simvastatin + pioglitazone treatment re-
duced IL-6, TNF-α, resistin, ADMA and MMP-9 com-
pared to the control group (p < 0.001). All treatments
increased adiponectin plasma levels (p < 0.001 for all).
Higher plasma adiponectin and lower hsCRP concentra-
tions were found simultaneously in the combined treat-
ment group.
Treatment effects on epicardial adipose tissue
Pioglitazone alone and simvastatin + pioglitazone treat-
ment were associated with a lower mean percentage posi-
tive area of CD68+/macrophages, CD45/T-lymphocytes,
TNF-α, IL-6, leptin and resistin in the EAT fragments com-
pared to controls (p < 0.001). Conversely, a significantly
higher mean percentage positive area for adiponectin was
observed (Figures 1 and 2). No significant differences in
the mean percentage positive area for CD20/B-lympho-
cytes were observed between pioglitazone alone and the
control group (Figure 1).
Figure 2 Immunohistochemical staining in the EAT:
components. (A) Immunohistochemical staining for inflammatory
cells in the EAT. CD68+: macrophages; CD45 T: T-lymphocytes; CD20
B: B-lymphocytes; TNF-α: tumoral necrosis factor alpha; IL-6: interleukin
6. CD45 T and CD20 B cells formed inflammatory clusters close to the
edge of and around vessels of the EAT sections in the simvastatin
group, but the center of the fat fragment was free of inflammatory
cells. 200X. See text for details. (B) Immunohistochemical staining for
pro- and anti-inflammatory cytokines in the EAT. CD68+: macrophages;
CD45 T: T-lymphocytes; CD20 B: B-lymphocytes; TNF-α: tumoral
necrosis factor alpha; IL-6: interleukin 6. CD45 T and CD20 B cells
formed inflammatory clusters close to the edge of and around vessels
of the EAT sections in the simvastatin group, but the center of the fat
fragment was free of inflammatory cells. 200X. See text for details.
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tory cells and cytokines were distributed over the adipose
tissue area in the control group. CD45 T-lymphocytes and
CD20 B-lymphocytes formed inflammatory clusters close
to the edge and around vessels of the adipose tissue in the
simvastatin group, but the center of the fat fragment was
free of inflammatory cells (Figure 2). Therefore, the mean
percentage positive area was larger in the simvastatin
group compared to the control group (p < 0.05) (Figure 1).Correlation between plasma values and tissue biomarkers
We investigated whether the treatment effects on plasma
biomarkers of inflammation produced corresponding ef-
fects on EAT. Positive correlations between plasma cyto-
kines and correspondent cytokines in EAT were found
after simvastatin, pioglitazone and pioglitazone + simva-
statin treatments (Figure 3). TNF-α after treatment with
simvastatin (r = −0.025, p = 0.33) and leptin after treat-
ment with pioglitazone (r = −0.877, p < 0.0001) showed
negative correlations. A positive correlation was found
between serum hsCRP and the percentage of macro-
phages in EAT, which indicates simultaneous reductions
in plasma and tissue values (Figure 3F). No correlations
between plasma lipid variables and tissue inflammatory
variables were observed.
Discussion
This study found that macrophages infiltration and pro-
inflammatory cytokines, TNF-α, IL-6, leptin and resistin,
were decreased in the EAT of CAD/MS patients treated
with simvastatin or pioglitazone, either as monotherapy
or in combination. Furthermore, these treatments were
also associated with an increased presence of adiponec-
tin, an anti-inflammatory cytokine secreted by EAT.
These findings reflected the observations in plasma
because a positive correlation between the percentage
area of macrophages in EAT and plasma hsCRP after
treatments was observed. T- and B-lymphocytes and
macrophage clusters were concentrated near the edge or
around blood vessels in EAT fat fragments of patients
treated with simvastatin, which is a novel observation.
Simvastatin + pioglitazone treatment was associated with
significantly lower plasma hsPCR, IL-6, TNF-α, resistin,
ADMA and MMP-9 compared to the control group.
Higher plasma adiponectin and lower hsCRP concentra-
tions in this group occurred simultaneously, which indi-
cated a predominance of the anti-inflammatory effect. The
lowest plasma leptin, resistin and MCP-1 values were
found in patients treated with simvastatin alone. These
findings are consistent with Jialal et al. [21], who observed
that pravastatin, atorvastatin or simvastatin therapy signifi-
cantly reduced hsCRP levels, which further supports an
anti-inflammatory effect of statins. The PIOSTAT Study
[22] found that, non-diabetic patients with cardiovascular
disease and elevated hsCRP levels showed significant anti-
inflammatory effects of pioglitazone that were comparable
to 40 mg simvastatin. Furthermore, these authors showed
that pioglitazone + simvastatin had additive effects on
hsCRP with a reduction greater than 40%, but only for pa-
tients without MS. Pioglitazone, as a monotherapy and in
combination, significantly reduced MMP-9 [23]. MMP-9
levels were also elevated in patients with diabetes mellitus,
and treatment with glitazones effectively reduced the levels
of this enzyme [24,25].
Figure 3 Correlations between plasma and EAT inflammatory variables. (A) IL-6; (B) TNF-α; (C) Leptin. (D) Resistin; (E) Adiponectin (F) EAT
macrophages and plasma hsCRP. TNF-α: tumor necrosis factor alpha; IL-6: interleukin 6; hsCRP: high-sensitivity C-reactive protein. See text
for details.
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with plasma cytokines and inflammatory markers also
modify the inflammatory response in EAT of CAD/MS
patients. Therefore, the mean percentage positive area
with macrophages, T-lymphocytes, TNF-α, IL-6, leptin
and resistin was significantly lower in EAT fragments
after 90 days of pioglitazone only or simvastatin + pio-
glitazone therapies than the control group. EAT is a
source of inflammatory cytokines, and this finding is
considerably important. An augmented inflammatory re-
sponse is associated with significant macrophage infiltra-
tion, which makes local adipose tissue deposits a
cardiovascular risk factor [6,7,9]. This hypothesis is sup-
ported by Suganami and Hirata [9,26], who suggestedthat a vicious cycle of infiltrating macrophages and adi-
pocytes augments the inflammatory response in adipose
tissue, especially in obesity-associated metabolic abnor-
malities, such as insulin resistance and diabetes. CAD
patients with MS and type 2 diabetes were treated with
pioglitazone, and this therapy was associated with de-
creased IL-1β, IL-1Ra and IL-10 mRNA expression in
EAT. Pro- and anti-inflammatory genes were differen-
tially increased in EAT and selectively reduced following
pioglitazone treatment [27].
We observed that the positive area for adiponectin
was five times lower in CAD/MS untreated patients than
after pioglitazone alone or simvastatin + pioglitazone
therapies. Furthermore, positive correlations were found
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in EAT after simvastatin, pioglitazone and pioglitazone +
simvastatin treatments. A positive correlation between
plasma hsCRP and the mean percentage of area to macro-
phage in EAT was also shown. TNF-α after simvastatin
treatment and leptin after pioglitazone treatment were
negatively correlated, which indicated a differential effect
in tissue and plasma. The decreased leptin in EAT follow-
ing TZD treatment demonstrates adipose depot-specific
responsiveness [28,29] or alternatively indicates that TZDs
induce translational or posttranslational changes that in-
crease protein levels without increasing mRNA levels [30].
The high leptin plasma concentrations in these circum-
stances are most likely due to production from subcutane-
ous adipose tissue [28]. However, Iacobelis et al. showed
significantly lower adiponectin expression in epicardial fat
isolated from patients with CAD [31]. Ouchi et al. ob-
served a significant inverse correlation between CRP and
adiponectin mRNA levels in human adipose tissue from
patients with documented coronary atherosclerosis [32].
Patients with MS expressed lower EAT adiponectin levels
than patients without MS [33]. Iacobellis et al. showed
peripheral adiponectin levels and epicardial fat adiponec-
tin protein expression were the best correlates of left cor-
onary artery adiponectin,. They showed that intracoronary
adiponectin levels reflect systemic adiponectin levels. Epi-
cardial adipose tissue could partially contribute to adipo-
nectin levels in the coronary circulation [34], although
that intracoronary plasma adiponectin rapidly and signifi-
cantly increases in patients with CAD after CABG [35].
We also showed that T- and B-lymphocytes and macro-
phage clusters concentrated near the edge or around
blood vessels in fat fragments of patients treated with sim-
vastatin alone, but the center of the fat fragments was free
of inflammatory cells. One possible explanation for these
findings is that cell residues were driven to tertiary lymph-
oid organs, which are ectopic accumulations of lymphoid
cells that arise under environmental influences, especially
during chronic inflammation. This hypothesis is supported
by the observation that prolonged inflammatory cytokine
production and/or lymphoid chemokine expression is suf-
ficient to induce lymphoid neogenesis [36]. Additionally,
lymph nodes during inflammation are characterized by an
increase in blood flow and T- and B-lymphocyte migration
[37]. Finally, clinical therapies can reverse the clusters of
lymphoid cells via cleansing of the inflammation-inducing
agent [38].
The present study demonstrated the novel ability of sim-
vastatin and pioglitazone to reduce plasma and tissue
inflammation simultaneously. This finding may represent
one mechanism that these drugs protect the cardiovascular
system against hypercholesterolemia and hyperglycemia.
These observations extend our understanding of the
actions of therapeutic interventions that might interferewith EAT and potentially contribute to the control mecha-
nisms involved in the pathogenesis of coronary atheroscler-
osis and decrease the cardiovascular risk.
Study limitations
The sample size was small, but it was sufficient for the
proposed objective. The results do not allow us to estab-
lish firm conclusions about drug efficacy because this was
a non-randomized trial without pre- and post-treatment
data. However, this analysis was not the main objective of
the study. Rather, we were primarily interested in the
correlations of plasma/tissue actions. We found significant
positive correlations between plasma and EAT effects of
simvastatin, pioglitazone and their combination.
Conclusions
Pioglitazone, simvastatin or combination treatment in
CAD and MS patients substantially reduced epicardial
adipose tissue and plasma inflammatory markers. These
tissue effects may contribute to the control of coronary
atherosclerosis progression and may be inferred from
plasmatic findings.
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